Asia Pacific Cell Therapy Market To Reach $2.77 Billion By 2030

Asia Pacific Cell Therapy Market Growth & Trends

The Asia Pacific cell therapy market size is anticipated to reach USD 2.77 billion in 2030 and is expected to grow at a CAGR of 22.49% from 2025 to 2030 Rapid advancements in regenerative medicine are anticipated to provide effective solutions for chronic conditions. A substantial number of companies in the growing markets, such as India and South Korea, are striving to capitalize on the untapped opportunities in the market, thereby driving the market.

The growth is greatly benefitted by the fund and regulatory support from government bodies and regulatory agencies. For instance, in August 2020, the government of South Korea passed an Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine to establish a regulatory system for patient safety during quality control and clinical trials, and to strengthen the regulatory support for regenerative medicine development.

The implementation of the act is expected to enhance clinical studies and approvals of regenerative medicine in South Korea. Furthermore, CAR-T and TCR T-cell therapies have already revolutionized hematologic cancer treatment. With the onset of the COVID-19 pandemic, scientists are deciphering its potential against the novel coronavirus. The concept of using T cells against chronic viral infections, such as HIV and hepatitis B, has already been proposed.

Based on the previous research insights, Singapore-based Duke-NUS medical school’s emerging infectious diseases research program demonstrated the utility of these immunotherapies in treating patients with COVID-19 infection. Thus, an increase in research for use of cell therapies for COVID-19 treatment is expected to drive the market in Asian countries. In April 2021, a team of researchers from Japan used induced pluripotent stem cells (iPS) to find drugs that can effectively inhibit the coronavirus and other RNA viruses.

 Request a free sample copy or view report summary: Asia Pacific Cell Therapy Market Report

Asia Pacific Cell Therapy Market Report Highlights

• The segment is also driven by the rapid advances in stem cell research which exhibits the potential to effectively address the unmet demand of pharmaceutical and biotech entities, as well as healthcare professionals in disease management

• On the other hand, the clinical use segment is expected to register a significant growth rate during the forecast period owing to the success of CAR-T and other cellular therapies in recent times

• Furthermore, the declining price of stem cell therapy products is anticipated to boost sales in this segment coupled with rising demand for effective alternatives to conventional therapies against various chronic indications

• This can be owed to relatively more application of cellular therapies in the management of various cancer types such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma

• Japan has emerged as the leading Asian market, which can be attributed to its fast growth as a hub for research on regenerative medicine

• On the other hand, Singapore and India are anticipated to witness the fastest growth over the forecast period owing to the presence of improving financing programs to support and advance cell therapy product development in the countries

Asia Pacific Cell Therapy Market Segmentation

Grand View Research has segmented the Asia Pacific cell therapy market report based on therapy type, therapeutic area, and region:

Asia Pacific Cell Therapy Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)

• Allogeneic Therapies                                     

  • Stem Cell Therapies                       

    • Hematopoietic Stem Cell Therapies         

    • Mesenchymal Stem Cell Therapies          

  • Non-stem Cell Therapies                              

    • Keratinocytes & Fibroblast-based Therapies        

    • Others 

• Autologous Therapies                                   

  • Stem Cell Therapies                       

    • BM, Blood, & Umbilical Cord-derived Stem Cells

    • Adipose derived cells     

    • Others 

  • Non-Stem Cell Therapies                             

    • T-Cell Therapies

      • CAR T Cell Therapy

      • T Cell Receptor (TCR)-based

    • Others 

Asia Pacific Cell Therapy Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Cardiovascular Disease (CVD)

• Musculoskeletal Disorders

• Dermatology

• Others

Asia Pacific Cell Therapy Country Outlook (Revenue, USD Million, 2018 - 2030)

• China

• Japan

• India

• South Korea

• Australia

List of Key Players in Asia Pacific Cell Therapy Market

• Kolon TissueGene, Inc.

• JCR Pharmaceuticals Co., Ltd.

• MEDIPOST

• PHARMICELL Co., Ltd.

• ANTEROGEN. CO., LTD

• Bristol-Myers Squibb Company

• Novartis AG

• Gilead Sciences, Inc.

• Curocell, Inc.

• JW Therapeutics (Shanghai) Co., Ltd.

• STEMPEUTICS RESEARCH PVT LTD